A client has a body mass index (BMI) of 30.5 and has been diagnosed with schizophrenia. Which medication is indicted for this diagnosis and has least effect on BMI?

Choice A reason: Olanzapine is well-known for causing significant weight gain and metabolic disturbances. It has one of the highest risks among antipsychotics for increasing BMI, fasting glucose, and lipid levels. Prescribing olanzapine to a client who already has a BMI of 30.5 (obese) would likely exacerbate their metabolic risk and cardiovascular profile. Choice B reason: Haloperidol is a first-generation antipsychotic that is relatively weight-neutral. However, it carries a high risk of extrapyramidal side effects and tardive dyskinesia. While it has a minimal effect on BMI, second-generation agents like aripiprazole are generally preferred for their broader efficacy and better overall tolerability profile in modern clinical practice. Choice C reason: Lurasidone is another second-generation antipsychotic with a relatively low risk of weight gain. However, aripiprazole is traditionally cited in clinical literature and FDA labeling as having one of the most favorable metabolic profiles regarding weight neutrality. Both are better than olanzapine, but aripiprazole remains a primary choice for weight-conscious prescribing. Choice D reason: Aripiprazole is a second-generation antipsychotic characterized by partial dopamine agonism. It is specifically noted for its "metabolic neutrality," meaning it has a very low propensity for causing weight gain or significant changes in BMI compared to other atypicals. For a client with an existing BMI of 30.5, aripiprazole is an ideal pharmacological choice to prevent further weight-related health complications.